WNT, RAS or phosphoinositide 3-kinase signaling pathways control specific stages of ovarian follicular development. To analyze the functional interactions of these pathways in granulosa cells during follicular development in vivo, we generated specific mutant mouse models. Stable activation of the WNT signaling effector b-catenin (CTNNB1) in granulosa cells results in the formation of premalignant lesions that develop into granulosa cell tumors (GCTs) spontaneously later in life or following targeted deletion of the tumor suppressor gene Pten. Conversely, expression of oncogenic KRAS G12D dramatically arrests proliferation, differentiation and apoptosis in granulosa cells, and consequently, small abnormal folliclelike structures devoid of oocytes accumulate in the ovary. Because of the potent anti-proliferative effects of KRAS G12D in granulosa cells, we sought to determine whether KRAS G12D would block precancerous lesion and tumor formation in follicles of the CTNNB1-mutant mice. Unexpectedly, transgenic Ctnnb1;Kras-mutant mice exhibited increased GC proliferation, decreased apoptosis and impaired differentiation and developed early-onset GCTs leading to premature death in a manner similar to the Ctnnb1;Pten-mutant mice. Microarray and reverse transcription-PCR analyses revealed that gene regulatory processes induced by CTNNB1 were mostly enhanced by either KRAS activation or Pten loss in remarkably similar patterns and degree. The concomitant activation of CTNNB1 and KRAS in Sertoli cells also caused testicular granulosa cell tumors that showed gene expression patterns that partially overlapped those observed in GCTs of the ovary. Although the mutations analyzed herein have not yet been linked to adult GCTs in humans, they may be related to juvenile GCTs or to tumors in other tissues where CTNNB1 is mutated. Importantly, the results provide strong evidence that CTNNB1 is the driver in these contexts and that KRAS G12D and Pten loss promote the program set in motion by the CTNNB1.
Introduction
Granulosa cells are the most proliferative cell type in the ovary (Rao et al., 1978; Robker and Richards, 1998) . Because of this it is surprising that granulosa cell tumors (GCTs; classified among sex cord/stromal neoplasms) are relatively rare in mammals. This may be determined by apoptosis that is a potent mechanism for eliminating granulosa cells in follicles that fail to differentiate or by luteinization, which terminates granulosa cell proliferation (Tilly et al., 1995) and leads to the non-dividing luteal phenotype (Richards, 1994) . Despite their rarity, GCTs remain the most common ovarian cancer subtype in most domestic species. For reasons that are not completely understood, women are particularly prone to develop cancers arising from the ovarian surface epithelium, and for this reason GCTs only represent around 5% of all human ovarian cancer (Jubb et al., 1993; Schumer and Cannistra, 2003) . GCTs can also occur in the testis (Dilworth, 1991) . Despite the impact of GCTs on domestic species and humans, the molecular mechanisms underlying the etiology of this disease are not yet entirely clear, only a limited number of mouse models have been generated (Matzuk et al., 1992; Pangas et al., 2008; Edson et al., 2010) and their relevance to domestic and human GCTs remains to be clearly determined.
Recent studies indicate that stage-specific activation of the WNT/FZD/CTNNB1/TCF cascade has critical roles in controlling normal follicular development and granulosa cell tumor formation (Boyer et al., 2009a) . If components of canonical WNT pathway are inappropriately activated or disrupted, granulosa cell fate decisions and follicular growth are dramatically altered (Vainio et al., 1999; Boerboom et al., 2005; Boerboom et al., 2006; Lague et al., 2008; Boyer et al., 2009a , Boyer et al., 2010 . Wnt4-null mice provided the first evidence that the WNT/b-catenin (CTNNB1) canonical pathway exerts potent effects on embryonic gonadal development by suppressing male gonad formation and facilitating ovarian development (Vainio et al., 1999) . Conversely, expression of a stable, activate, mutant form of CTNNB1 selectively in granulosa cells leads to the formation of precancerous lesions that eventually become granulosa cell tumors (Boerboom et al., 2005 (Boerboom et al., , 2006 . In follicles where granulosa cells escape early transformation but express stable activated CTNNB1, follicle-stimulating hormone (FSH)-mediated induction of Cyp19a1 and granulosa cell proliferation are enhanced, whereas luteinizing hormone (LH)-mediated granulosa cell differentiation is completely blocked . Moreover, FSH and other signaling factors can activate the WNT signaling cascade leading to transcriptional activation of CTNNB1 (Parakh et al., 2006; . The WNT/CTNNB1 pathway intersects with multiple signaling cascades and transcription factors to dramatically alter cell function during development and in cancer (Wodarz and Nusse, 1998; Jin et al., 2008; Boyer et al., 2009a) . For example, FOXL2 functions coordinately with WNT4 to regulate formation of the embryonic ovary and impacts granulosa cell proliferation and differentiation in the postnatal ovary (Uda et al., 2004; Ottolenghi et al., 2007; Boyer et al., 2010; Jamieson et al., 2010; Wang et al., 2010) . Moreover, a specific mutation (C134W) in the human Foxl2 gene has recently been shown to be expressed in nearly all adult GCTs, indicating that it has a critical role in this disease in women (Kalfa et al., 2008; Kobel et al., 2009; Shah et al., 2009; Jamieson et al., 2010) .
The RAS pathway is also critical for normal ovarian function . LH induction of the epidermal growth factor-like factors amphiregulin, epiregulin and b-cellulin and their activation of the epidermal growth factor receptor/RAS/extracellularsignal-regulated kinase 1/2 (ERK1/2) pathway in granulosa cells of preovulatory follicles regulate ovulation, oocyte maturation and the terminal differentiation of granulosa cells to non-dividing luteal cells (Park et al., 2004; Ashkenazi et al., 2005; Conti et al., 2005; Hsieh and Conti, 2005; Hsieh et al., 2007; Fan et al., 2009b) . When the KRAS/ERK1/2 pathway is activated selectively in granulosa cells at earlier stages of follicular development by expressing a mutant KRAS G12D , the Kras G12D -mutant granulosa cells cease dividing and fail to differentiate (Fan et al., 2008a, b) . Because apoptosis is also blocked, abnormal follicle-like structures persist and accumulate in the ovary leading to premature ovarian failure (Fan et al., 2008b) . Thus, expression of Kras G12D in granulosa cells does not exhibit oncogenic activity, at least in this context. Rather, it causes granulosa cells to exit the cell cycle and this is associated with elevated levels of the tumor suppressor, phosphatase and tensin homolog (PTEN; Fan et al., 2009a, b; Fan et al., 2008b) .
Components of the PTEN/phosphoinositide 3-kinases (PI3K)/AKT/FOXO pathway are expressed in granulosa cells and are activated not only by insulin-like growth factor 1 (IGF1) but also by FSH, LH and the epidermal growth factor-like factors (Gonzalez-Robayna et al., 2000; Richards et al., 2002; Fan et al., 2008a) . Disruption of Pten in granulosa cells reduces apoptosis, increases the number of ovulating follicles and the persistence of luteal cell structures (Fan et al., 2008a) . However, the disruption of Pten alone rarely leads to GCTs (Lague et al., 2008) , perhaps because the levels of PTEN are relatively low in normal granulosa cells (Fan et al., 2008a, b) . Conversely, overexpression of a stable active form of FOXO1, a downstream target of AKT, severely impairs granulosa cell responses to FSH and LH in culture (Liu et al., 2009) .
In the ovary, the proliferative effects of a stable mutant form of Ctnnb1 in granulosa cells are markedly enhanced if the tumor suppressor Pten is deleted coordinately in granulosa cells of the Ctnnb1-mutant strain leading to rapid tumor growth (Lague et al., 2008) . Furthermore, when mutations in Ctnnb1 and Pten are directed to Sertoli cells, GCT formation in occurs in the testis (Boyer et al., 2009b) , indicating that Sertoli cells are also susceptible to the combined tumorigenic effects of these two oncogenes.
The potent anti-proliferative effects of mutant KRAS G12D in granulosa cells of small follicles appear to be irreversible because proliferation in the KRAS G12D -mutant granulosa cells is not markedly reversed by the loss of the tumor suppressor Pten in this context (Fan et al., 2009a; . These results documented that granulosa cells, unlike ovarian surface epithelial cells (Fan et al., 2009a) , are highly resistant to these specific oncogenic factors. Therefore, we reasoned that KRAS G12D might block the proliferative and transformation-dependent effects of CTNNB1 in GCTs of the ovary and testis. Therefore, we sought to determine if tumor formation and growth initiated by mutant CTNNB1 could be altered (suppressed) in granulosa cells by co-expressing KRAS
G12D
. Additionally, we sought to determine whether there were cell-and stage-specific effects in response to expressing mutant CTNNB, KRAS G12D or the loss of PTEN. Thus, we have compared gonad morphology, gene expression profiles and functions in mice expressing mutant Ctnnb1 and Kras or mutant Ctnnb1 and loss of Pten driven by mice expressing either Cyp19Cre or Amhr2Cre. Although these mouse models combine mutations that have not yet been identified in human GCTs, the data obtained provide novel evidence on how these pathways may interact in other tissues where CTNNB1 mutations are common.
Results
Premalignant lesions and GCTs occur in the Ctnnb1;C-Cre mice Previous studies showed that targeted expression of dominant stable CTNNB1 in granulosa cells using the Ctnnb1 tm1Mmt (simplified herein to Ctnnb1) and Amhr2 tm3(cre)Bhr (A-cre) alleles led to the formation of abnormal follicles characteristic of precancerous lesions (Boerboom et al., 2005 (Boerboom et al., , 2006 . Ultimately, the (Ctnnb1 tm1Mmt/ þ ;Amhr2 tm3(cre)Bhr / þ ) (Ctnnb1;A-cre) mice developed GCTs after 6 months of age. Because CTNNB1, KRAS and PTEN mutants drive GCTs in ovary and testis JS Richards et al Amhr2Cre is expressed early during embryonic ovarian development, it was hypothesized that a clonal population of cells in the developing gonad was vulnerable to effects of oncogenic CTNNB1. To determine whether expressing dominant stable CTNNB1 at later stages of follicular development could also impair granulosa cell functions leading to precancerous lesions and GCTs, we used the Cyp19Cre (Tg(CYP19A1-cre)1jri) (C-Cre) mice, in which recombinase activity is first detected approximately at postnatal day 15-20 and is increased in preovulatory follicles (unpublished). The Ctnnb1 tm1Mmt/ þ ; Tg(CYP19A1-cre)1jri (Ctnnb1;C-Cre) mice lived for 6-8 months ( Figure 1a ) but also eventually succumbed to GCTs. The ovaries of these mice exhibited visible precancerous lesions between 4 and 6 weeks of age ( Figure 1c ) similar to those observed previously in the Ctnnb1;A-Cre mice (Boerboom et al., 2005 (Boerboom et al., , 2006 . All wild-type (WT) littermates remained viable and exhibited normal ovarian morphology at 4, 6 and 8-12 weeks of age (Figures 1a and c) .
GCTs form in the Ctnnb1;Kras G12D ;C-Cre and Ctnnb1;Pten;C-Cre-mutant mice To analyze the specific effects of oncogenic Kras G12D versus loss of Pten in the Ctnnb1;C-Cre-mutant mice, the Kras tm4Tyj/ þ ;Ctnnb1 tm1Mmt/ þ ; Tg(CYP19A1-cre)1jri (Ctnnb1;Kras;C-Cre) and Pten tm1Hwu/ tm1Hwu ;Ctnnb1 tm1Mmt/ þ ; Tg(CYP19A1-cre)1jri (Ctnnb1;Pten;C-Cre) mice were generated and checked twice weekly for evidence of Figure 1 Ovarian granulosa cell tumor formation is enhanced when mutant active CTNNB1 is co-expressed with mutant KRAS G12D or in the absence of PTEN. Ctnnb1;C-Cre mice as well as Ctnnb1;Kras;C-Cre and Ctnnb1;Pten C-Cre mice were generated to determine the effects of stable active KRAS G12D and the loss of Pten in the mice expressing stable active CTNNB1 selectively in granulosa cells of growing follicles. (a) Survival rates for mice of the different genotypes indicates that the Ctnnb1;Pten;C-Cre mice succumbed to tumor volume first followed by the Ctnnb1; Kras;C-Cre mice and the Ctnnb1;C-Cre mice. (b) Gross morphology of tumor-bearing ovaries present in a Ctnnb1; Kras;C-Cre mouse at 3 months compared with a WT mouse at the same age. (c) Histological sections of ovaries from WT and mutant mice at different ages. The images show normal follicles and corpora lutea (CL) in WT mice, precancerous lesions (white arrows) in the Ctnnb1;C-Cre mice and tumors (GCTs) in the Ctnnb1; Kras;C-Cre and Ctnnb1;Pten;C-Cre mice. Tumors of the Ctnnb1;Pten;C-Cre mice grow faster than those expressing Kras G12D .
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Because granulosa cells present in the abnormal follicles of the Kras;C-Cre mice are non-proliferative (Fan et al., 2008b) , we predicted that Kras G12D would suppress the proliferative effects of mutant Ctnnb1. Unexpectedly, precancerous lesions appeared in the Ctnnb1;Kras; C-Cre mice between 4 and 5 weeks of age ( Figure 1c ) and bilateral tumors were observed by 3 months of age ( Figure 1b ). All Ctnnb1;Pten;C-Cre mice died within 2-3 months of age due to tumor burden ( Figure 1a ; not shown). Histological analyses showed evidence of precancerous lesions by 3 weeks of age and large GCTs by 6-8 weeks of age (Figure 1c) . These results are similar to the Ctnnb1;Pten; A-Cre mice that we reported earlier (Lague et al., 2008) . Although the tumors of the Ctnnb1;Kras;C-Cre mice grew more slowly than those of the Ctnnb1;Pten;C-Cre mice, they grew faster than those in the Ctnnb1;C-Cre mice, indicating that the presence of Kras G12D enhances tumor growth mediated by CTNNB1 but does so at a slower rate compared with the loss of Pten.
Fertility is impaired in the Ctnnb1;Kras;C-Cre-and Ctnnb1;Pten;C-Cre-mutant mice We next sought to determine the physiological consequences of either expressing KRAS G12D or disrupting Pten in the Ctnnb1;C-Cre-mutant mice. As shown, serum levels of FSH and LH were elevated in the Ctnnb1;Kras;C-Cre-and Ctnnb1;Pten;C-Cremutant mice at 6 weeks of age compared with WT controls, whereas serum estradiol and progesterone levels were reduced in the mutants (Figure 2a) . Figure 2 Granulosa cell differentiation is blocked in the double mutant mice. (a) Serum levels of FSH and LH are elevated, whereas estradiol and progesterone are low in the Ctnnb1;Pten;C-Cre and Ctnnb1;Kras;C-Cre mice compared with controls at 6-8 weeks of age. (b) Granulosa cell-specific marker genes are suppressed in ovaries of the Ctnnb1;Pten;C-Cre and Ctnnb1;Kras;C-Cre-mutant mice that contain GCTs. Genes controlling cell proliferation are increased, whereas a cell cycle inhibitor is decreased. (c) Induction of granulosa cell marker genes in immataure mice by treatment with eCG (48 h) is suppressed in the Ctnnb1;Kras;C-Cre mice compared with WT.
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Despite elevated gonadotropins, granulosa cell differentiation was blocked as indicated by the loss of granulosa cell-specific marker genes (Fshr, Lhcgr, Cyp19a1, Cyp11a1 Inha, Amh) in ovaries of the Ctnnb1;Kras;C-Cre and Ctnnb1;Pten;C-Cre mice at 6 weeks ( Figure 2b ). Granulosa cells of immature mice before major tumor formation also failed to respond to exogenous eCG, as indicated by the lack of induction of specific granulosa cell marker genes in immature Ctnnb1;Kras;C-Cre and Ctnnb1;Pten;C-Cre mice treated with eCG to induce follicular development (Figure 2c ).
Granulosa cell proliferation is increased and apoptosis is decreased in the GCTs
To determine whether proliferation was altered in the Ctnnb1;Kras;C-Cre and Ctnnb1;Pten;C-Cre granulosa cells compared with WT controls, 5-bromo-2 0 -deoxyuridine (BrdU) uptake and levels of phospho-histone-H3 were examined. To determine whether apoptosis was altered TUNEL (terminal deoxynucleotidyl transferase 2 0 -deoxyuridine 5 0 -triphosphate nick-end labeling) assays detecting DNA fragmentation and immunostaining for FOXO1, an apoptosis related factor in granulosa cells (Liu et al., 2009 ) that is absent in the abnormal follicle present in the Kras;C-Cre mice (Fan et al., 2008b) were performed. FOXO1 and DNA fragmentation were absent/reduced in the GCTs of the Ctnnb1;Kras;C-Cre-and Ctnnb1;Pten;C-Cre-mutant mice but were detected in growing follicles of WT and Ctnnb1;C-Cre ovaries (Figure 3a) . Immunolabeling of BrdU and phospho-histone-H3 was highest in the ovaries (GCTs) of the Ctnnb1;Pten;C-Cre mice at 5-6 weeks of age, compared with that observed in the Ctnnb1;Kras;C-Cre-mutant mice and WT mice Figure 3a and b). Thus, apoptosis is reduced and proliferation is increased in the GCTs of the double mutant mice.
Levels and activation of CTNNB1, PTEN and KRAS pathway components in mutant and WT ovaries
To determine the expression levels of CTNNB1, PTEN and components of the KRAS pathway in the mutant mouse ovaries, ovaries were collected and cell lysates were prepared for western blot analyses. As shown, levels of CTNNB1 were low in ovaries of immature WT mice compared with ovaries in the Ctnnb1;C-Cre, Ctnnb1;Kras;C-Cre and Ctnnb1;Pten;C-Cre mice ( Figure 4 ). The results also confirmed the expression of the mutant CTNNB1 in the relevant ovaries and that levels of PTEN protein were reduced selectively in the Ctnnb1;Pten;C-Cre ovaries. Levels of phospho-ERK1/2 and phospho-P90RSK, downstream targets of KRAS were elevated in the Ctnnb1;Kras;C-Cre and Ctnnb1;C-Cre samples but were low in the Ctnnb1;Pten;C-Cre granulosa cells. Of particular note, the levels of phospho-AKT and phospho-GSK3b were elevated in all samples expressing mutant CTNNB1 (Figure 4 ).
Gene expression profiles reveal a remarkable similarity among the genes expressed in granulosa cells of each mutant genotype To determine specific genes regulated by CTNNB1 in granulosa cells in vivo, microarray analyses were carried out using RNA samples prepared from ovaries of 4-week old control, Ctnnb1;C-Cre-, Ctnnb1;Kras;C-Creand Ctnnb1;Pten;C-Cre-mutant mice. In silico analyses determined that many genes were upregulated (619) or downregulated (203) by expression of dominant stable CTNNB1 alone ( Figure 5 ). Of the 619 upregulated genes, 130 (21%) were specific to CTNNB1 alone, whereas 440 (71%) were upregulated not only in the Ctnnb1;Pten;C-Cre-mutant mice but also in the Ctnnb1;Kras;C-Cre-mutant strain. These included CTNNB1 target genes many of which are positive (Wnt4, Wnt2, Wnt6, Wnt5b, Wnt16, Tcf7 and Tcf12) as well as negative (Wif1, Notum, Nkd1 and Axin2) regulators of the canonical WNT pathway (Table 1, Figure 6 ). Of note, two negative regulators of the WNT/CTNNB1 pathway, Ndk2 and Dkk2 were increased in the Ctnnb1;Kras;C-Cre-and Ctnnb1;Pten;CCre-mutant cells but not in the Ctnnb1;C-Cre-mutant cells, whereas upregulation of Ndk1 and Dkk4 were selectively upregulated in the Ctnnb1;C-Cre-mutant cells. Expression of several genes was verified by realtime reverse transcription-PCR and in situ hybridization ( Figure 6 ; Supplementary Figures 1 and 2 ). Of the 203 downregulated genes, 22 (11%) were specific for CTNNB1 alone, whereas 177 (87%) were also downregulated in both double mutant strains. Within the latter cluster, many of the genes were either granulosa cell specific (Fshr, Nr5a2, Esr2, Prkar2b and Fst) or oocyte specific (Zp3, Oosp1, Nlrp4, Gdf9 and Gpr1) but also included one tumor suppressor (Rassf4) that binds RAS and is associated with RAS-dependent apoptosis (Table 1) .
Equally impressive was the high number of genes that were upregulated in the CTNNB1 expressing cells by either KRAS G12D (2136) or the loss of Pten (1977; Figure 5 ). Of these, a large number (1362) were upregulated in both the Ctnnb1;Pten;C-Cre (64%) and Ctnnb1;Kras;C-Cre (69%) mutant ovaries. These results were unexpected given the markedly different effects of expressing Kras G12D (Fan et al., 2008b) or disrupting Pten alone (Fan et al., 2008a, b) or in combination in granulosa cells (Table 1; Fan et al., 2008a) . A notable number of upregulated genes were related to RAS signaling, including the Ret and Met proto-oncogenes, Etv5 a potential regulator of RET (Tyagi et al., 2009) , Epidermal growth factor receptor pathway substrate 8, Eps8 (Xu et al., 2009) , Rrad, Rassf8, several guanine nucleotides exchange factors (Arhgef2, 3, 5, 12 and Rapgef4, also known as Epac) and Rab family members (Rab6, 20 and 24) involved in intracellular trafficking. Components of the PI3K pathway (Pik3c3 and Pik3r3) were increased approximately threefold and protein kinase C, b (Prkcb) was elevated B30-fold (Table 1) . The parallel upregulation of components of the RET/ MET/RAS and PI3K pathways by KRAS G12D or loss of Pten underscores the overlapping impact of these mutations and indicates that these two pathways are tightly linked in these cancer cells.
An impressive number of genes were also downregulated and showed extensive overlap between in the Ctnnb1;Kras;C-Cre (83%) and Ctnnb1;Pten;C-Cre (82%) mutant ovaries. Most genes downregulated in this cluster reflected the loss of granulosa cell markers, including several components of the IGF1 pathway (Igf1, Igf1r, Irs2, Socs2 and Foxo1) and the inhibin/ activin/Bmpr1b pathway. Because the mutant ovaries lack corpora lutea and are essentially devoid of oocytes, markers of these cell types were also markedly reduced (Table 1) . However, three of the most highly downregulated genes were osteoglycin (Ogn) that encodes a blocker of metastasis, leucocyte cell derived chemotaxin (Lect1) that encodes a potent blocker of angiogenesis Figure 3 Proliferation and apoptosis are altered in the GCTs of the mutant mice at 6 weeks of age. (a) Immunostaining of FOXO1 is high in growing follicles present in the ovaries of WT and mutant mice but is absent in the precancerous lesions (black arrows) of the Ctnnb1;C-Cre mice, the abnormal follicles (black arrows) present in ovaries of Kras;C-Cre mice and the GCTs of the double mutant mice. (b, c) Granulosa cell proliferation (BrdU uptake and phospho-histone H3 staining) is enhanced in the GCTs of the Ctnnb1;Pten;C-Cre mice compared with WT and Ctnnb1;Kras;C-Cre mice, whereas apoptosis is reduced in the GCTs.
and Uchl1 that encodes a ubiquitin carboxy-terminal hydrolase that is associated with cancer progression in a cell context-specific manner (Fellenberg et al., 2010; Hussain et al., 2010) . Other genes of particular interest that were increased in the tumors include Apcdd1, Enpp2, Etv1, Fst, Cnr1, Sox7 and Tbx3 (Table 1, Figure 6 ). Ctnnb1;Kras;A-Cre mice develop granulosa cell tumors of the testis As male Ctnnb1;Pten;A-Cre male mice develop granulosa cell tumors of the testis (GCTT) (Boyer et al., 2009b) , we next sought to determine whether activated KRAS and dominant-stable CTNNB1 could combine to cause GCTT in the Ctnnb1;Kras;A-Cre model. Male Ctnnb1;A-Cre mice developed a seminiferous tubule degeneration phenotype by 5 weeks of age, resulting in progressive loss of spermatogenesis, testicular atrophy with reduced testis size and sterility (Figures 7a, b and d; Table 2 ), which was consistent with previous reports (Boyer et al., 2008; Tanwar et al., 2010) . Although male Kras;A-Cre mice were phenotypically normal and had grossly unaltered fertility and spermatogenesis (Figures 7a-c, Table 2 and data not shown), Ctnnb1;Kras;A-Cre mice had a degenerative phenotype similar to that observed in the Ctnnb1;A-Cre model, but with a somewhat earlier onset (B4 weeks). Furthermore, GCTT that were histologically indistinguishable from those observed in the Ctnnb1;Pten;A-Cre model were found in most Ctnnb1;Kras;A-Cre testes after 4-5 months of age (Figure 7a , e, f). GCTTs in Ctnnb1; Kras;A-Cre mice grew more slowly than those of Ctnnb1;Pten;A-Cre mice, resulting in testis/tumor weights at 4-6 months of age that were similar to those of Ctnnb1;Pten;A-Cre mice at 5 weeks of age (Figures 7a  and b and Table 2 ). The tumors did not spread or metastasize, and did not compromise viability or animal well-being up to 8 months of age (not shown). The diagnosis of GCTT in the Ctnnb1;Kras;A-Cre testes was supported by the detection of ectopic expression of FOXL2 ( Figure 7g ) and Wnt4 (Figure 8 ), both markers of early granulosa cell differentiation (Ottolenghi et al., 2007) . FOXL2 expression was in fact comparable with levels expressed in ovarian tissue, as had been previously observed in the Ctnnb1;Pten;A-Cre model.
Granulosa cell tumors of the ovary and testis express some similar and some distinct CTNNB1 target genes Because GCTs develop in the ovaries and testes of the Ctnnb1;Pten;A-Cre-mutant mouse strain (Boerboom et al., 2005 (Boerboom et al., , 2006 Lague et al., 2008; Boyer et al., 2009a, b) , we used these mice to determine whether the tumors in the ovary and testis express similar or distinct genes and whether the expression of Kras G12D would impact the growth of GCTs in the Amhr2-Cre expressing mouse strains. Ovaries and testes were collected from control and Ctnnb1;A-Cre-, Kras;A-Cre-, Pten;A-Cre-, Ctnnb1;Pten;A-Cre-and Ctnnb1;Kras;A-Cre-mutant mice at distinct ages when tumor sizes were similar (based on published and preliminary studies). Ovarian and testis weights were determined (Table 2 ) and the tissues used to prepare RNA. Real-time reverse transcription-PCR was used to determine the expression of selected genes that were prominently regulated on the microarrays and in tumors of the C-Cre-mutant strains (Figures 5 and 6 ). As shown, many CTNNB1 target genes were slightly or significantly upregulated in ovaries of the Ctnnb1;A-Cre mice and were dramatically (130) and downregulation of (22) a limited number of genes, respectively. In Ctnnb1;Kras;C-Cre and Ctnnb1;Pten;C-Cre mouse ovaries, there are overlapping gene expression profiles of genes upregulated (440) and downregulated (177) in the Ctnnb1;C-Cre mouse ovaries. In addition, there is a large number of genes are upregulated (1362) or downregulated in ovaries of both the Ctnnb1;Kras;C-Cre and Ctnnb1;Pten;C-Cre-mutant mice. (Figure 8 ). These results confirm those obtained in the C-Cre strains. Two genes (Nr5a2 and Nr0b1) were reduced in ovaries of the double mutant mice and three (Foxo3a, Tcf12 and Wnt4) showed no change. When the same genes were analyzed in the testis samples, several CTNNB1 target genes (Axin2, Enpp2, Etv1, Nfat5, Ndk1, Tcf12 and Wnt4) were increased in the Ctnnb1;A-Cre alone mutant testes. Several of these genes were also increased in the Ctnnb1;Pten;A-Cre mice, whereas expression of Axin2, Ndk1and Peg3 increased most dramatically in the Ctnnb1;Kras;A-Cremutant mice. The increased expression of Foxo3 and Wnt4 and the lack of expression of Cd83 and Wnt16 in testes of the Ctnnb1;A-Cre mice were notably different from the expression patterns of these genes observed in the ovaries of mice of the same genotype.
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Discussion
These studies document for the first time that oncogenic KRAS G12D as well as loss of Pten promote the altered genetic program set in motion by dominant stable CTNNB1 that drives granulosa proliferation and cell fate decisions (Boerboom et al., 2006; Boyer et al., 2009a, b) . Most impressive and unexpected were the phenotypic data showing that oncogenic KRAS G12D and loss Pten exert remarkably similar effects in magnitude and direction, leading to early granulosa cell tumor formation and growth in ovaries of both the Ctnnb1; C-Cre and Ctnnb1;A-Cre mouse strains. These results were totally unexpected based on the completely opposite effects of expressing KRAS G12D alone (Fan et al., 2008b) compared with disrupting Pten alone (Fan et al., 2008b) in granulosa cells. Although premature expression of KRAS G12D in granulosa cells of small follicles causes granulosa cell cycle arrest and elevated levels of PTEN in these cells (Fan et al., 2008a) , loss of Pten enhances granulosa cell proliferation, leading infrequently to GCTs (Lague et al., 2008; Fan et al., 2008a, b) . Therefore, we predicted that expression of KRAS G12D would block or reduce granulosa cell proliferation and the appearance of precancerous lesions observed in the in the Ctnnb1;A-Cre and Ctnnb1;C-Cremutant mice. However, contrary to this hypothesis, the Ctnnb1;Kras;A-Cre-and Ctnnb1;Kras;C-Cre-mutant mice develop precancerous lesions similar to those observed in the Ctnnb1;A-Cre and Ctnnb1;C-Cre mouse strains. Furthermore, GCTs develop in these mice with 100% penetrance. Although the growth rate of the GCTs in the Ctnnb1;Kras;A-Cre-and Ctnnb1;Kras; C-Cre-mutant mice is slower than in the Ctnnb1; Pten;C-Cre and Ctnnb1;Pten;A-Cre mice, the phenotypic outcomes are ultimately similar. Collectively, these results indicate that the potent mechanisms by which KRAS G12D alone acts to block or terminate granulosa cell proliferation in small antral follicles is reversed and/or superceded by events initiated and driven by dominant stable CTNNB1. Moreover, because ovaries of the Ctnnb1;Pten;A-Cre mice expressed reduced levels of KRAS and ERK1/2 phosphorylation compared with Abbreviations: IGF, insulin-like growth factor; PI3K, phosphatidylinositol 3-kinase; WT, wild type. RNA was extracted from whole ovaries of control (WT) mice, Ctnnb1-Cyp19-cre, Kras;Pten-Cyp19-cre, Ctnnb1;Kras-Cyp19-cre and Ctnnb1;PtenCyp19-cre mice at 6 weeks of age. The RNA samples (two/genotype) were analyzed in duplicate using the Affymetrix Mouse 430.2 array chip. All mutant mRNA values were expressed relative to that detected in WT samples. The table shows notable genes upregulated and downregulated in ovaries of the Ctnnb1;C-Cre-, Ctnnb1;Kras;C-Cre-and Ctnnb1;Pten C-Cremutant mice.
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the Ctnnb1;C-Cre and Ctnnb1;Kras;C-Cre mice, it appears that the presence of KRAS and ERK1/2 reduces the rate of tumor growth but cannot completely block proliferation as observed when KRAS G12D is expressed alone in the Kras;C-Cre mice (Fan et al., 2008b) .
Equally impressive, and supporting the phenotypic outcome of the different Ctnnb1-mutant strains, was the high degree of similarity among the gene expression profiles of the precancerous lesion-and tumor-bearing ovaries in the Ctnnb1;Kras;C-Cre-and Ctnnb1;Kras; A-Cre-and Ctnnb1;Pten;C-Cre-and Ctnnb1;Pten; A-Cre-mutant female mice. Many of the genes upregulated by mutant CTNNB1 alone in the precancerous ovaries were expressed at even higher levels in ovaries of the Ctnnb1;Kras;C-Cre-and Ctnnb1;Kras;A-Cre-and Ctnnb1;Pten;C-Cre-and Ctnnb1;Pten;A-Cre-mutant mice. Notable among these were negative regulators of the WNT/CTNNB1 pathway observed in our previous studies, including Wif1, Axin2 and Ndk1 (Boerboom et al., 2006; . Additional CTNNB1 target genes, identified in the more extensive microarray analyses presented in this study, include the positive regulators, such as Wnt16, as well as the negative regulators such as Apcdd1, Enpp2, Etv1, Peg3, Nkd2, Notum and Tbx3 of the canonical WNT pathway. Abbreviations: control, A-Cre; CA, Ctnnb1;A-Cre; CKA, Ctnnb1;Kras;A-Cre; CPA, Ctnnb1;Pten A-Cre; KA, Kras;A-Cre; PA, Pten A-Cre. Note that tumors occurred earlier and grew faster (based on gonad weight) in the CPA male and female mice compared with the CKA-mutant mice. Asterisk (*) denotes Po0.05; bold indicates values different from control. CTNNB1, KRAS and PTEN mutants drive GCTs in ovary and testis JS Richards et al APCDD1 (adenomatosis polyposis coli downregulated 1) is a membrane-bound glycoprotein that interacts with WNT3 and LRP5 to inhibit WNT signaling (Takahashi et al., 2002; Shimomura et al., 2010) . In colorectal cancer cells, upregulation of the Apcdd1 gene promotes cell proliferation (Takahashi et al., 2002) . On the basis of dramatic induction of Apcdd1 expression in GCTs of the ovary and testis, it may be a key driver of CTNNB1 in granulosa cell tumor formation and growth. Enpp2 encodes ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (autotaxin) that is important for lipid signaling, proliferation and cell migration (Tania et al., 2010) . The Ets variant transcription factor Etv1 impacts gastrointestinal tumor formation where it is regulated by a KITL/mitogenactivated protein linase1/3 pathway (Chi et al., 2010) . Etv5 is expressed in granulosa and Sertoli cells and regulates Ret expression and signaling in the testis (Eo et al., 2008; Tyagi et al., 2009) . Because Etv5 is a CTNNB1 target gene that increases expression of Ret, the increase in Etv5 likely leads to enhanced activation of this pathway and tumor growth as in other tissues (Tyagi et al., 2009) . Cnr1 and Tbx3 are CTNNB1 target genes known to impact proliferation and pluripotency and thus may also contribute to the GCT formation (Trazzi et al., 2010; Wagner et al., 2010) . Peg3 is a maternally imprinted gene that has the potential to inhibit apoptosis (Broad et al., 2009) . CD83 and NFAT5 are normally related to immune cell functions (Breloer and Fleischer, 2008; Drews-Elger et al., 2009) . Their roles in GCTs remain unknown.
The data generated using the two different mouse strains expressing Cre recombinase document unequivocally that CTNNB1 can alter granulosa cell fate decisions and differentiation at early (Amhr2Cre) as well as at later (Cyp19Cre) stages of follicle development by blocking the expression of many granulosa cell-specific marker genes, such as Cyp19, Nr5a2, Lhcgr and Fshr (Figures 5, 6, 8; Boerboom et al., 2006 . However, the mutant granulosa cells continue to express markers characteristic of granulosa cells at early stages of gonadal development and follicle formation, such as Wnt4 and Foxl2. These results suggest that the CTNNB1 expressing granulosa cells are locked into a specific, primordial stage of differentiation. That CTNNB1-expressing granulosa cells are highly susceptible to transformation by either Kras G12D or loss of Pten indicates that each potently and rapidly enhances the effects of CTNNB1 in these cells. These results provide strong evidence that if CTNNB1 or other genetic lesions that directly upregulate the canonical WNT pathway are mutated or deleted, CTNNB1 is likely to be the strong driver irrespective of what other mutations occur. Moreover, many of the genes that were expressed at elevated levels in the GCTs of the ovary and/or testis are known to be targets of CTNNB1 in other cancer cell types and impact cancer cell growth and invasiveness (Takahashi et al., 2002; Chi et al., 2010; Harper et al., 2010; Heinrich and Corless, 2010; Jane-Valbuena et al., 2010; Jiang et al., 2010; Shimomura et al., 2010; Tania et al., 2010; Wagner et al., 2010 ).
The molecular mechanisms by which expression of Kras G12D and loss of Pten exert such similar effects on the genetic program initiated by stable CTNNB1 remain to be determined. However, increased phosphorylation of CTNNB1 by activated AKT and the loss of FOXO1 may both contribute to enhanced transcriptional activity of CTNNB1 (Boyer et al., 2009a, b) . Furthermore, AKT phosphorylation was increased in both mutant models and expression of specific components of the PI3K and RAS signaling pathways were increased to a similar extent in tumor cells of the Ctnnb1;Kras-and Ctnnb1;Pten-mutant mice, indicating that these two pathways converge in the presence of active CTNNB1. This convergence may involve the upregulation of the proto-oncogenes Ret and Met that occurred in the double mutant mice and may be mediated by phosphorylation and increased expression of Etv5 and/or Etv1.
An important issue raised by our findings is their potential relatedness to the pathogenesis of adult and juvenile forms of GCTs in women. It has recently been shown that the vast majority of adult form GCTs in women bear a common mutation (C134W) in the FOXL2 gene, suggesting a pivotal role for FOXL2 in one or more phases of disease development (Shah et al., 2009; Jamieson et al., 2010) . However, it remains to be determined if and how the disease processes initiated by the manipulation of the WNT/CTNNB1, PI3K/AKT and/or KRAS pathways in our models relates to the mutant FOXL2-driven human disease. Although our data seem to indicate that Foxl2 mRNA levels are not meaningfully altered in the various transgenic models, FOXL2 activity may be modulated by other means, such as post-translational modifications or cofactor binding (Pisarska et al., 2011) The biological activities of mutant FOXL2 are as yet poorly understood, and only a handful of studies have begun to elucidate the mechanisms by which it may contribute to tumorigenesis (Lee et al., 2005; Fleming et al., 2010; Kim et al., 2011) . It is plausible that mutant FOXL2 initiates cellular processes resulting in the hyperactivation of the WNT/CTNNB1, PI3K/AKT and/or KRAS pathways that may enhance tumor development. For example, FOXL2 and WNT4 are critical for granulosa cell specification, both regulate aromatase and both promote follicle development (Uda et al., 2004; Moumne et al., 2008; Garcia-Ortiz et al., 2009; Boyer et al., 2010; Fleming et al., 2010) . If this also occurs in adult GCTs, the mutant cells may be more responsive to WNT/CTNNB1 activation. In addition, KGN cells that are derived presumably from an adult GCT express the FOXL2 C134W mutant and exhibit constitutive activation of ERK1/2 (Steinmetz et al., 2004) . Chemical or small-interfering RNA disruption of ERK1/2 blocked proliferation indicating that activation (not a mutation) of a RAS-ERK1/2cascade is critical for the proliferative potential of these cells. Because RAS can activate the PI3K pathway, this pathway may also contribute to the FOXL2-mutant phenotype. Hence, it is not yet clear if mutant FOXL2 is sufficient or necessary to drive GCT formation. Another possibility is that the molecular mechanisms involved in tumor development in our mouse models are partially or completely unrelated to FOXL2. In this regard, the juvenile form of GCT in humans is characterized by an earlier (often prepubertal) onset, is not associated with FOXL2 mutations (Shah et al., 2009; Jamieson et al., 2010) and the molecular mechanisms controlling this GCT form are ill defined (Jamieson et al., 2010) . It therefore remains to be determined if the mechanisms involved in juvenile GCT development are more closely related to those that are activated in the mouse GCT models described herein, and therefore that the latter could be thought of as being more analogous to the juvenile rather than the adult human GCT disease. Clearly, many more studies are needed to clarify the drivers and helpers involved at various phases of this complex disease in the ovary.
On the basis of gene profiling results in the GCTs of the ovary and the observations that cell morphology and tumor architecture are similar in GCTs of the ovary and testis (Boyer et al., 2009a, b) , we anticipated similar patterns of gene expression in the GCTs of the testis and ovary. However, there are distinct as well as similar gene expression patterns between the GCTs in ovary and testis. Because the gene expression profiles of tumors in the Ctnnb1;Kras;A-Cre male mice are more similar to those of the ovarian GCTs than are the profiles in the Ctnnb1;Pten;A-Cre strain, tumors in the Ctnnb1; Kras;A-Cre male mice seem to be more differentiated toward the granulosa cell phenotype than the tumors of Ctnnb1;Pten;A-Cre male mice. The higher levels of Wnt4 and Foxl2 mRNA expression in the Ctnnb1;Kras; A-Cre testes are consistent with the idea that these cells have assumed a primordial granulosa cell-like genetic program. Their slower growth rate likely relates to the effects of KRAS G12D that impair granulosa cells proliferation in the ovary. Because Wnt4 and Foxl2 but not Wnt16 are induced in the GCTs of the testis, these factors may serve as critical positive regulators, perhaps with some functions redundant of WNT16 in this context.
Explanations for the major differences between the Ctnnb1;Pten;A-Cre and Ctnnb1;Kras;A-Cre gene expression profiles in the GCTs of the testis are not completely obvious and are somewhat surprising given the dramatic similarities in the GCTs in the ovaries of mice with these genotypes. However, the differences may relate to when mutant CTNNB1 is first expressed as well as the time of onset and speed of tumor development. For example, tumors in the 5-week Ctnnb1;Pten;A-Cre model are approximately the same size as the tumors in the 5-month old Ctnnb1;Kras; A-Cre mice. Although these times were selected to compare early growth stages of tumor development across genotypes, selection criteria based on size may overlook critical molecular events being driven by the loss of Pten versus the expression of KRAS G12D at specific stages of cell differentiation. Although cell morphology appears similar in both models, cell morphology is not always an indicator of molecular changes. The lack of more dramatic changes in gene expression in the male GCTs may also reflect the presence of more testicular tissue associated with the tumors than in the ovaries. This may 'dilute out' some of the genes that are prominently expressed in the tumor cells.
In summary, our results show that stable expression of CTNNB1 in granulosa or Sertoli cells alters their genetic program and predisposes them to oncogenic transformation by either expression of mutant KRAS G12D or loss of PTEN. Because KRAS G12D alone is a potent suppressor of granulosa cell proliferation, these oncogenic effects of KRAS G12D were unexpected. Moreover, the striking similarities in the gene expression patterns in the GCTs of the ovary and testis when either mutant KRAS G12D is expressed or Pten is lost in the mutant CTNNB1 cells provide strong evidence that CTNNB1 is the driver in these contexts and that KRAS G12D and Pten loss promote the program set in motion by the CTNNB1. Although the mutations analyzed herein have not yet been linked to adult GCTs in humans, they may be related to juvenile GCTs or to tumors in other tissues where CTNNB1 is mutated. In this regard, these results may have clinical relevance and help explain why tumor growth is so rapid and pervasive in tissues where mutations in Ctnnb1 as well as alterations in the RAS or PI3K pathways are common. ) (Li et al., 2002) were used to generate mice harboring granulosa cells specific mutations of each gene alone or in combination using the two cell-specific Cre recombinase strains of mice Amhr2 tm3(cre)Bhr / þ ) Amhr2-Cre (Jamin et al., 2002) and Tg (CYP19A1-Cre)1jri (Cyp19-Cre) (Fan et al., 2008a, b) . All the mutant mouse strains are in the C57BL/6 background.
Materials and methods

Animals
Histology, TUNEL assay, immunohistochemistry and BrdU uptake Ovaries were fixed in 4% paraformaldehyde, embedded in Optional Cutting Temperature compound (Sakura Finetek USA Inc., Torrance, CA, USA) and stored at À70 1C before the preparation of 7 mm sections. Serial sections were stained with hemotoxylin and eosin according to established procedures . The TUNEL assays were carried out using the ApopTagPlus apoptosis detection kit (Chemicon International, Temecula, CA, USA) as reported previously (Fan et al., 2008 a, b) . Sections were also probed with primary antibodies to specific proteins (FOXO1, BrdU and phospho-histone H3 from Cell Signaling Technology, Danvers, MA, USA); and (BrdU from Sigma Chemical Company, St Louis, MO, USA), as indicated in the text and secondary Alexa Fluor 594-or 488-conjugated goat anti-rabbit immunoglobulin G antibodies (Molecular Probes, Life Technologies, Carlsbad, CA, USA) as previously described (Fan et al., 2009a, b ). Slides were mounted using VectaShield with 4 0 ,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA). Digital images were captured using a Zeiss Axioplan 2 microscope (Zeiss, Munich, Germany) with Â 5-63 objectives. For all the experiments, exposure time was kept the same for control and mutant samples. Proliferation was analyzed by BrdU incorporation into cells of mice injected with 50 mg/kg BrdU in saline 2 h before killing the mice. Ovaries were embedded as above, sections and immnostained for BrdU (Sigma Chemical Company).
Western blot analyses
Cell extracts containing 30 mg protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to PVDF membranes (Millipore Corp., Bedford, MA, USA) and analyzed as previously (Fan et al., 2009a, b) using primary antibodies to CTNNB1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and PTEN, phospho-90RSK1/2/3, phospho-ERK1/2, phospho-AKT, phospho-GSK3b, FOXL2 (Cell Signaling Technology) and ACTIN (Cytoskeleton Inc., Denver, CO, USA) at 1:1000 dilutions or as indicated in the figure legend.
RNA isolation, microarray analyses and quantitative PCR Total RNA was isolated using the RNeasy Mini kit (Qiagen Sciences, Germantown, MD, USA). RNA quality was assessed and then riboprobes were generated from WT and mutant RNA and hybridized to Mouse 430.2 microarray chips (Affymetrix, Santa Clara, CA, USA) in the Microarray Core Facility of the Baylor College of Medicine as previously described (Hernandez-Gonzalez et al., 2006) . Microarray data were analyzed as previously reported using the Robust Multiarray Averaging function (Irizarry et al., 2003) from the Affy package (v1.5.8) through the BioConductor software (http://www.bioconductor.org/; Gentleman et al., 2004) . The microarray data have been deposited to GEO; the accession number is GSE27656 (http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?token ¼ blczregkwwekmrw&acc ¼ GSE27656). Reverse transcription was carried out using the SuperScript One-Step reverse transcription-PCR system with Platinum Taq kit (Invitrogen, Carlsbad, CA, USA). The QPCR was performed using the Rotor-Gene 3000 thermocycler (Corbett Research, Sydney, Australia). Relative levels of mRNAs were calculated using Rotor-Gene 6.0 software and normalized to the levels of endogenous b-actin in the same samples.
Statistical analyses
The data are represented as means ± s.e.m. Quantitative PCR data is expressed at the ratio of WT (n ¼ 1) to mutant. Data were analyzed by using GraphPad Prism Programs (analysis of variance or t-test; GraphPad Prism, San Diego, CA, USA) and Dunnett's post hoc test after analysis of variance to compare all genotypes to the control. Values were considered significantly different if Pp0.05 or Pp0.01.
